Jefferies reiterates USD 185 target: Gilead Sciences stock trades 16.38 percent below it
Published on 10/26/2026 at 17:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Jefferies reiterated a USD 185.00 target on October 23, 2026.
- Gilead's next quarterly results are scheduled for October 29, 2026.
- Gilead Sciences stock costs EUR 142.13 at Lang & Schwarz on October 26, 2026 at 5:16 p.m. CEST, plus 1.51 percent versus the Xetra close of October 23, 2026, and 0.97 percent below the USD 160.51 high.
Jefferies Financial Group reiterated its Buy rating and USD 185.00 price target for Gilead Sciences on October 23, 2026, according to MarketBeat. Against Gilead's USD 158.96 Nasdaq price at 12:28 p.m. ET on October 26, 2026, that target stands 16.38 percent above the stock.
Gilead's next quarterly results are scheduled for October 29, 2026, with the company listing the release and webcast on its corporate website.
Stock stays near its yearly high
Gilead's Nasdaq price of USD 158.96 on October 26, 2026 sits 0.97 percent below the 52-week high of USD 160.51. The 52-week low is USD 114.02, placing the stock 39.41 percent above that floor.
The current USD 197.1 billion market capitalization gives the price position added weight. The stock's reported price-to-earnings ratio is negative 59.51, while the latest trading volume reached 2,371,784 shares on October 26, 2026.
What does the target imply?
Jefferies' USD 185.00 target is 16.38 percent above the Nasdaq price used for the comparison. The estimate is also above the USD 159.81 average target from 29 analysts, which MarketBeat classifies as a Moderate Buy consensus.
That spread leaves the scheduled October 29 results as the next dated test for the valuation. The company reported second-quarter revenue of USD 7.80 billion, compared with USD 7.40 billion consensus, in figures cited by MarketBeat.
Price holds above the Xetra close
Gilead Sciences was trading at EUR 142.13 at Lang & Schwarz on October 26, 2026 at 5:16 p.m. CEST, plus 1.51 percent versus the Xetra close of October 23, 2026 at EUR 140.02. The move places the euro quote within reach of its reported primary-market high in a session that followed the Xetra close. The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences market data
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 26, 2026, 5:16 p.m. CEST): EUR 142.13
- Change versus Xetra close: plus 1.51 percent
- Xetra close (October 23, 2026): EUR 140.02
- Market capitalization: USD 197.1 billion (as of October 26, 2026)
- 52-week range: USD 114.02-160.51 (as of October 26, 2026)
- Sector / Industry: Health Care / Biotechnology
- Next earnings date: October 29, 2026
Market context: Market report S&P 500.
